

## MEDICAL POLICY – 7.01.175

## Temporarily Implanted Nitinol Device (iTind) for Benign Prostatic Hyperplasia

BCBSA Ref. Policy: 7.01.175

Effective Date: April 1, 2024


Last Revised: Jan. 1, 2025

## RELATED MEDICAL POLICIES:

2.01.49 Transurethral Water Vapor Thermal Therapy and Transurethral Water Jet Ablation (Aquablation) for Benign Prostatic Hyperplasia

Select a hyperlink below to be directed to that section.

[POLICY CRITERIA](#) | [DOCUMENTATION REQUIREMENTS](#) | [CODING](#)  
[RELATED INFORMATION](#) | [EVIDENCE REVIEW](#) | [REFERENCES](#) | [HISTORY](#)

 Clicking this icon returns you to the hyperlinks menu above.

## Introduction

Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate gland that is common in men over age 50. The enlarged prostate gland presses against the urethra, the tube that carries urine from the bladder to the outside of the body. BPH can lead to: emptying the bladder more often, feeling a sudden need to empty the bladder, problems with fully emptying the bladder, problems with starting or maintaining a stream of urine, and waking up at night to go to the bathroom. BPH is usually treated with watchful waiting, lifestyle changes, medication, and surgery. Another way to treat BPH is by placing a device in the urethra for about a week. The goal is to help reshape the prostate tissue and reduce problems with emptying the bladder. The use of a temporarily implanted nitinol device to treat symptoms from BPH is unproven (investigational). More studies are needed to see if this type of treatment improves health outcomes.

**Note:** The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

## Policy Coverage Criteria

Device	Investigational
Temporarily implanted nitinol device (e.g., iTind)	The use of a temporarily implanted nitinol device (e.g., iTind) is considered investigational as a treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.

## Coding

Code	Description
<b>CPT</b>	
53865	Cystourethroscopy with insertion of temporary device for ischemic remodeling (ie, pressure necrosis) of bladder neck and prostate (new effective 1/01/2025)
53866	Catheterization with removal of temporary device for ischemic remodeling (ie, pressure necrosis) of bladder neck and prostate (new effective 1/01/2025)
53899	Unlisted procedure, urinary system
55899	Unlisted procedure, male genital system
<b>HCPCS</b>	
C9769	Cystourethroscopy, with insertion of temporary prostatic implant/stent with fixation/anchor and incisional struts (Nitinol, iTind device)

**Note:** CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

## Related Information

N/A

## Evidence Review



## Description

Benign prostatic hyperplasia (BPH) is a common condition in older individuals that can lead to increased urinary frequency, an urgency to urinate, a hesitancy to urinate, nocturia, and a weak stream when urinating. Temporarily implanted nitinol devices have been proposed as a minimally invasive alternative to transurethral resection of the prostate (TURP), considered the traditional standard treatment for symptomatic benign prostatic hyperplasia. The device is temporarily implanted into the obstructed prostatic urethra to facilitate tissue reshaping and improve urine outflow. The implant is typically removed after five to seven days of treatment.

## Background

### Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is a common disorder among older individuals that results from hyperplastic nodules in the periurethral or transitional zone of the prostate. The clinical manifestations of BPH include increased urinary frequency, nocturia, urgency or hesitancy to urinate, and a weak stream when urinating. The urinary tract symptoms often progress with worsening hypertrophy and may lead to acute urinary retention, incontinence, renal insufficiency, and/or urinary tract infection. Benign prostatic hyperplasia prevalence increases with age and is present in more than 80% of individuals aged 70 to 79 years.<sup>1</sup>

Two scores are widely used to evaluate BPH-related symptoms: the American Urological Association Symptom Index (AUASI) and the International Prostate Symptom Score (IPSS). The AUASI is a self-administered 7-item questionnaire assessing the severity of various urinary symptoms.<sup>2</sup> Total AUASI scores range from 0 to 35, with overall severity categorized as mild ( $\leq 7$ ), moderate (8-19), or severe (20-35).<sup>1</sup> The IPSS incorporates questions from the AUASI and a quality-of-life question or a "Bother score."<sup>3</sup>

Benign prostatic hyperplasia does not necessarily require treatment. The decision on whether to treat BPH is based on an assessment of the impact of symptoms on quality of life along with the potential side effects of treatment. For patients with moderate-to-severe symptoms (e.g., an AUASI score of  $\geq 8$ ), bothersome symptoms, or both, a discussion about medical therapy is reasonable. Benign prostatic hyperplasia should generally be treated medically first. Available medical therapies for BPH-related lower urinary tract dysfunction include  $\alpha$ -adrenergic blockers (e.g., alfuzosin, doxazosin, tamsulosin, terazosin, silodosin), 5 $\alpha$ -reductase inhibitors (e.g., finasteride, dutasteride), combination  $\alpha$ -adrenergic blockers and 5 $\alpha$ -reductase inhibitors, anti-muscarinic agents (e.g., darifenacin, solifenacin, oxybutynin), and phosphodiesterase-5 inhibitors



(e.g., tadalafil).<sup>1</sup> In a meta-analysis of both indirect comparisons from placebo-controlled studies (n=6333) and direct comparative studies (n=507), Djavan et al (1999) found that the IPSS improved by 30% to 40% and the Qmax score (mean peak urinary flow rate) improved by 16% to 25% in individuals assigned to  $\alpha$ -adrenergic blockers.<sup>4</sup> Combination therapy using an  $\alpha$ -adrenergic blocker and 5 $\alpha$ -reductase inhibitor has been shown to be more effective for improving IPSS than either treatment alone, with median scores improving by more than 40% over 1 year and by more than 45% over 4 years.

Patients who do not have sufficient response to medical therapy, or who are experiencing significant side effects with medical therapy, may be referred for surgical or ablative therapies. The American Urological Association (AUA) recommends surgical intervention for patients who have "renal insufficiency secondary to BPH, refractory urinary retention secondary to BPH, recurrent urinary tract infections (UTIs), recurrent bladder stones or gross hematuria due to BPH, and/or with lower urinary tract symptoms (LUTS) attributed to BPH refractory to and/or unwilling to use other therapies."<sup>5</sup> Transurethral resection of the prostate (TURP) is generally considered the reference standard for comparisons of BPH procedures.<sup>6</sup> In the perioperative period, TURP is associated with risks of any operative procedure (e.g., anesthesia risks, blood loss). Although short-term mortality risks are generally low, a large prospective study with 10,654 patients by Reich et al (2008) reported the following short-term complications: "failure to void (5.8%), surgical revision (5.6%), significant urinary tract infection (3.6%), bleeding requiring transfusions (2.9%), and transurethral resection syndrome (1.4%)."<sup>7</sup> Incidental carcinoma of the prostate was diagnosed by histologic examination in 9.8% of patients. In the longer term, TURP is associated with an increased risk of sexual dysfunction and incontinence.

The use of the iTind temporarily implanted nitinol device has been investigated as a minimally invasive treatment for lower urinary tract symptoms associated with BPH. With the use of a rigid cystoscope, the device is temporarily implanted into the obstructed prostatic urethra where three double intertwined nitinol struts configured in a tulip shape gradually expand.<sup>8</sup> The resulting circumferential force facilitates tissue reshaping via ischemic necrosis of the mucosa, resulting in urethral expansion and prostatic incisions that function as longitudinal channels to improve urine outflow.<sup>9</sup> The implant is typically removed after five to seven days of treatment. A distal nylon wire facilitates device retrieval which may be approached using a snare to pull the device into either a cystoscope sheath or an open-ended silicone catheter (20-22 Fr).<sup>10</sup> The first-generation TIND device had one extra strut and a pointed tip covered by a soft plastic material.



## Summary of Evidence

For individuals who have benign prostatic hyperplasia (BPH) with lower urinary tract symptoms who receive a temporarily implanted nitinol device (e.g., iTind), the evidence includes a meta-analysis, one randomized controlled trial (RCT), and two single-arm, multicenter, international prospective studies. Relevant outcomes are symptoms, functional outcomes, health status measures, quality of life, and treatment-related morbidity. One network meta-analysis compared the safety and efficacy of various minimally-invasive treatments for lower urinary tract symptoms associated with BPH, finding that iTind may result in worse urologic symptoms scores compared to TURP at short-term follow-up. One RCT compared the iTind device with a sham procedure and reported an improvement of at least 3 points on the IPSS scale at 3 months in 78.6% versus 60% of participants, respectively (p=.029). However, corresponding changes in overall IPSS, IPSS QOL, peak urinary flow rate, Sexual Health Inventory for Men (SHIM), and International Index of Erectile Function (IIEF) scores were not significantly different between groups. One single-arm study reported significant improvements in symptoms and functional outcomes through greater than four years. A subsequent single-arm study enrolling men desiring to preserve ejaculatory function reported no significant change in the SHIM total score and a statistically significant improvement on the Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MSHQ-EJD) at 6 months. No studies have directly compared iTind to established alternatives; however, an RCT comparing iTind with the UroLift prostatic urethral lift procedure is currently ongoing. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this review are listed in [Table 1](#).

**Table 1. Summary of Key Trials**

NCT No.	Trial Name	Planned Enrollment	Completion Date
<b>Ongoing</b>			
<a href="#">NCT03395522<sup>a</sup></a>	One-arm, Multi-center, International Prospective Study to Assess the Efficacy of Medi-tate Temporary Implantable Nitinol Device (iTind) in Subjects With	149	Apr 2025 (ongoing)



NCT No.	Trial Name	Planned Enrollment	Completion Date
	Symptomatic Benign Prostatic Hyperplasia (BPH) (MT-06)		
NCT04757116 <sup>a</sup>	A Post-Market, Prospective, Randomized, Controlled, Multicenter International Study to Assess the Safety of the Temporarily Implanted Nitinol Device (iTind) Compared to the UroLift® System in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH) (MT-08)	250	Dec 2025 (recruiting)
<b>Unpublished</b>			
NCT04579913 <sup>a</sup>	A Multi-center, International Prospective Follow up Study to Assess the Safety and Efficacy of the iTind Procedure After Three to Five Years of Follow Up	17	Terminated (COVID-19)

NCT: national clinical trial.

<sup>a</sup> Denotes industry-sponsored or cosponsored trial.

## Practice Guidelines and Position Statements

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Guidelines or position statements will be considered for inclusion if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

## American Urological Association

In 2021, the American Urological Association (AUA) published guidelines on the surgical evaluation and treatment of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH).<sup>5</sup> These guidelines do not address the use of temporarily implanted nitinol devices.

A 2023 amendment to the 2021 AUA guideline stated that temporary implanted prostatic devices are an option for individuals with BPH, LUTS, prostate volume of 25 to 75 grams, and



who lack an obstructive median lobe.<sup>25</sup> This recommendation was based on expert opinion due to an absence of sufficient evidence.

## National Institute for Health and Care Excellence

In 2022, the National Institute for Health and Care Excellence (NICE) issued an interventional procedures guidance on prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by BPH.<sup>26</sup> The recommendation noted that the evidence on the use of these devices is limited in quantity and quality. Therefore, the procedure should only be used with special arrangements for clinical governance, consent, and audit or research.

## Medicare National Coverage

There is no national coverage determination.

## Regulatory Status

In April 2019, the iTind System (Olympus; previously, Medi-Tate Ltd., Hadera, Israel) was granted a de novo 510(k) classification by the U.S. Food and Drug Administration (FDA) (DEN190020; product code: QKA). The new classification applies to this device and substantially equivalent devices of this generic type (e.g., K210138). The iTind System is intended for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men aged 50 and older.

## References

1. Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. *N Engl J Med*. Jul 19 2012; 367(3): 248-57. PMID 22808960
2. Barry MJ, Fowler FJ, O'Leary MP, et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. *Med Care*. Apr 1995; 33(4 Suppl): AS145-55. PMID 7536866
3. O'leary MP. Validity of the "bother score" in the evaluation and treatment of symptomatic benign prostatic hyperplasia. *Rev Urol*. 2005; 7(1): 1-10. PMID 16985801



4. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. *Eur Urol.* 1999; 36(1): 1-13. PMID 10364649
5. Lerner LB, McVary KT, Barry MJ, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART II-Surgical Evaluation and Treatment. *J Urol.* Oct 2021; 206(4): 818-826. PMID 34384236
6. Foster HE, Barry MJ, Dahm P, et al. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline. *J Urol.* Sep 2018; 200(3): 612-619. PMID 29775639
7. Reich O, Gratzke C, Bachmann A, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. *J Urol.* Jul 2008; 180(1): 246-9. PMID 18499179
8. Amparore D, De Cillis S, Volpi G, et al. First- and Second-Generation Temporary Implantable Nitinol Devices As Minimally Invasive Treatments for BPH-Related LUTS: Systematic Review of the Literature. *Curr Urol Rep.* Jul 05 2019; 20(8): 47. PMID 31278441
9. Fiori C, De Cillis S, Volpi G, et al. iTIND for BPH: Technique and procedural outcomes: A narrative review of current literature. *Turk J Urol.* Nov 2021; 47(6): 470-481. PMID 35118965
10. Balakrishnan D, Jones P, Somani BK. iTIND: the second-generation temporary implantable nitinol device for minimally invasive treatment of benign prostatic hyperplasia. *Ther Adv Urol.* 2020; 12: 1756287220934355. PMID 32655690
11. Rosen RC, Catania JA, Althof SE, et al. Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction. *Urology.* May 2007; 69(5): 805-9. PMID 17482908
12. Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. *Int J Impot Res.* 2005; 17(4): 307-19. PMID 15875061
13. Sønksen J, Barber NJ, Speakman MJ, et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. *Eur Urol.* Oct 2015; 68(4): 643-52. PMID 25937539
14. Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. *J Urol.* Nov 1995; 154(5): 1770-4. PMID 7563343
15. Roehrborn CG, Wilson TH, Black LK. Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial. *J Urol.* May 2012; 187(5): 1732-8. PMID 22425127
16. Porpiglia F, Fiori C, Bertolo R, et al. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up. *BJU Int.* Aug 2015; 116(2): 278-87. PMID 25382816
17. Porpiglia F, Fiori C, Bertolo R, et al. 3-Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction. *BJU Int.* Jul 2018; 122(1): 106-112. PMID 29359881
18. Franco JV, Jung JH, Imamura M, et al. Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis. *Cochrane Database Syst Rev.* Jul 15 2021; 7(7): CD013656. PMID 34693990
19. Chughtai B, Elterman D, Shore N, et al. The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial. *Urology.* Jul 2021; 153: 270-276. PMID 33373708
20. Amparore D, Fiori C, Valerio M, et al. 3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. *Prostate Cancer Prostatic Dis.* Jun 2021; 24(2): 349-357. PMID 33005003
21. Amparore D, De Cillis S, Schulman C, et al. Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results. *Minerva Urol Nephrol.* Dec 2023; 75(6): 743-751. PMID 37350585





22. De Nunzio C, Cantiello F, Fiori C, et al. Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study. *World J Urol.* Jun 2021; 39(6): 2037-2042. PMID 32851439
23. Porphiglia F, Fiori C, Amparore D, et al. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up. *BJU Int.* Jun 2019; 123(6): 1061-1069. PMID 30382600
24. Kadner G, Valerio M, Giannakis I, et al. Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study. *World J Urol.* Dec 2020; 38(12): 3235-3244. PMID 32124019
25. Sandhu JS, Bixler BR, Dahm P, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023. *J Urol.* Jan 2024; 211(1): 11-19. PMID 37706750
26. National Institute for Health and Care Excellence (NICE). Interventional procedures guidance: prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia [IPG737]. September 21, 2022; <https://www.nice.org.uk/guidance/ipg737>. Accessed February 20, 2024.

## History

Date	Comments
03/01/23	New policy, approved February 14, 2023. Policy created with literature review through November 15, 2022. The use of a temporarily implanted nitinol device (e.g., iTind) is considered investigational as a treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Added CPT codes 53899 and 55899.
04/01/24	Annual Review, approved March 11, 2024. Policy updated with literature review through November 17, 2023. Policy statements unchanged.
01/01/25	Coding update. Added new CPT codes 53865 and 53866.

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2025 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.

